1887
Volume 2015, Issue 4
  • ISSN: 2305-7823
  • E-ISSN:

Abstract

It is believed that simultaneous targeting of two or more of the three pathogenic pathways of pulmonary arterial hypertension (the endothelin, nitric oxide, and prostacyclin pathways) is associated with additive or synergistic effects with subsequent increasing efficacy and improving outcomes. However, there is lack of evidence to guide the use of combination strategy among pulmonary arterial hypertension patients and many questions remain to be answered. One of these vital questions is whether the strategy of upfront initiation of combination therapy could improve patients outcomes compared to the strategy of initial monotherapy. The recently published AMBITION trial represents an important forward step towards answering this question by comparing a strategy of first-line combination therapy (ambrisentan and tadalafil) versus first-line monotherapy (ambrisentan or tadalafil) in patients with pulmonary arterial hypertension.

Loading

Article metrics loading...

/content/journals/10.5339/gcsp.2015.48
2015-11-13
2019-08-20
Loading full text...

Full text loading...

/deliver/fulltext/gcsp/2015/4/gcsp.2015.48.html?itemId=/content/journals/10.5339/gcsp.2015.48&mimeType=html&fmt=ahah

References

  1. [1]. Humbert   M., , Barst   RJ., , Robbins   IM., , Channick   EM., , Galiè   N., , Boonstra   A., , Rubin   LJ., , Horn   EM., , Manes   A., , Simonneau   G. . Combination of bosentan with epoprostenol in pulmonary arterial hypertension: BREATHE-2. . Eur Respir J . 2004; ;24: : 353– 359 .
    [Google Scholar]
  2. [2]. Galiè   N., , Barbera   JA., , Frost   A., , Ghofrani   HA., , Hoeper   MM., , McLaughlin   VV., , Peacock   AJ., , Simonneau   G., , Vachiery   JL., , Grünig   E., , Oudiz   RJ., , Vonk-Noordegraaf   A., , White   RJ., , Blair   C., , Gillies   H., , Miller   KL., , Harris   JH., , Langley   J., , Rubin   LJ., , AMBITION Investigators. . Initial use of Ambrisentan plus Tadalafil in pulmonary arterial hypertension. . New Engl J Med . 2015; ;379: 9 : 834– 844 .
    [Google Scholar]
  3. [3]. Galiè   N., , Humbert   M., , Vachieryc   JL., , Gibbs   S., , Lang   I., , Torbicki   A., , Simonneau   G., , Peacock   A., , Vonk Noordegraaf   A., , Beghetti   M., , Ghofrani   A., , Angel   M., , Sanchez   G., , Hansmann   G., , Klepetko   W., , Lancellotti   P., , Matucci   M., , McDonagh   T., , Pierard   LA., , Trindade   PT., , Zompatori   M., , Hoeper   M. . 2015 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension. The Joint Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS) Endorsed by: Association for European Paediatric and Congenital Cardiology (AEPC), International Society for Heart and Lung Transplantation (ISHLT) European Heart Journal Aug 2015, DOI: 10.1093/eurheartj/ehv317 .
  4. [4]. Fukuroda   T., , Fujikawa   T., , Ozaki   S., , Ishikawa   K., , Yano   M., , Nishikibe   M. . Clearance of circulating endothelin-1 by ETB receptors in rats. . Biochem Biophys Res Commun . 1994; ;199: : 1461– 1465 .
    [Google Scholar]
  5. [5]. Hirata   Y., , Emori   T., , Eguchi   S., , Kanno   K., , Imai   T., , Ohta   K., , Marumo   F. . Endothelin receptor subtype B mediates synthesis of nitric oxide by cultured bovine endothelial cells. . J Clin Invest . 1993; ;91: : 1367– 1373 .
    [Google Scholar]
  6. [6]. Girgis   RE., , Champion   HC., , Diette   GB., , Johns   RA., , Permutt   S., , Sylvester   JT. . Decreased exhaled nitric oxide in pulmonary arterial hypertension: response to bosentan therapy. . Am J Respir Crit Care Med . 2005; ;172: : 352– 357 .
    [Google Scholar]
  7. [7]. Liang   F., , Yang   S., , Yao   L., , Belardinelli   L., , Shryock   J. . Ambrisentan and tadalafil synergistically relax endothelin-induced contraction of rat pulmonary arteries. . Hypertension . 2012; ;59: : 705– 711 .
    [Google Scholar]
  8. [8]. Spence   R1., , Mandagere   A., , Harrison   B., , Dufton   C., , Boinpally   R. . No clinically relevant pharmacokinetic and safety interactions of ambrisentan in combination with tadalafil in healthy volunteers. . J Pharm Sci . 2009; ;98: 12 : 4962– 4974 .
    [Google Scholar]
  9. [9]. Paul   GA., , Gibbs   JS., , Boobis   AR., , Abbas   A., , Wilkins   MR. . Bosentan decreases the plasma concentration of sildenafil when coprescribed in pulmonary hypertension. . Br J Clin Pharmacol . 2005; ;60: : 107– 112 .
    [Google Scholar]
  10. [10]. McLaughlin   V., , Channick   RN., , Ghofrani   HA., , Lemarié   JC., , Naeije   R., , Packer   M., , Souza   R., , Tapson   VF., , Tolson   J., , Al Hiti   H., , Meyer   G., , Hoeper   MM. . Bosentan added to sildenafil therapy in patients with pulmonary arterial hypertension. . Eur Respir J . 2015; ;46: : 405– 413 .
    [Google Scholar]
  11. [11]. Hoeper   MM., , Bogaard   HJ., , Condliffe   R., , Frantz   R., , Khanna   D., , Kurzyna   M., , Langleben   D., , Manes   A., , Satoh   T., , Torres   F., , Wilkins   MR., , Badesch   DB. . Definitions and diagnosis of pulmonary hypertension. . J Am Coll Cardiol . 2013; ;62: Suppl : D42– D50 .
    [Google Scholar]
  12. [12]. Halpern   SD., , Taichman   DB. . Misclassification of pulmonary hypertension due to reliance on pulmonary capillary wedge pressure rather than left ventricular end-diastolic pressure. . Chest . 2009; ;136: : 37– 43 .
    [Google Scholar]
  13. [13]. Galiè   N., , Hoeper   MM., , Humbert   M., , Torbicki   A., , Vachiery   JL., , Barbera   JA., , Beghetti   M., , Corris   P., , Gaine   S., , Gibbs   JS., , Gomez-Sanchez   MA., , Jondeau   G., , Klepetko   W., , Opitz   C., , Peacock   A., , Rubin   L., , Zellweger   M., , Simonneau   G. . Guidelines for the diagnosis and treatment of pulmonary hypertension. The Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS), endorsed by the International Society of Heart and Lung Transplantation (ISHLT). . Eur Heart J . 2009; ;30: 20 : 2493– 2537 .
    [Google Scholar]
  14. [14]. Campo   A., , Mathai   SC., , Le Pavec   J., , Zaiman   AL., , Hummers   LK., , Boyce   D., , Housten   T., , Lechtzin   N., , Chami   H., , Girgis   RE., , Hassoun   PM. . Outcomes of hospitalisation for right heart failure in pulmonary arterial hypertension. . Eur Respir J . 2011; ;38: : 359– 367 .
    [Google Scholar]
  15. [15]. Haddad   F., , Peterson   T., , Fuh   E., , Kudelko   KT., , de Jesus Perez   V., , Skhiri   M., , Vagelos   R., , Schnittger   I., , Denault   AY., , Rosenthal   DN., , Doyle   RL., , Zamanian   RT. . Characteristics and outcome after hospitalization for acute right heart failure in patients with pulmonary arterial hypertension. . Circ Heart Fail . 2011; ;4: : 692– 699 .
    [Google Scholar]
  16. [16]. Sztrymf   B., , Souza   R., , Bertoletti   L., , Jaïs   X., , Sitbon   O., , Price   LC., , Simonneau   G., , Humbert   M. . Prognostic factors of acute heart failure in patients with pulmonary arterial hypertension. . Eur Respir J . 2010; ;35: : 1286– 1293 .
    [Google Scholar]
  17. [17]. Sachdev   A., , Villarraga   HR., , Frantz   RP., , McGoon   MD., , Hsiao   JF., , Maalouf   JF., , Ammash   NM., , McCully   RB., , Miller   FA., , Pellikka   PA., , Oh   JK., , Kane   GC. . Right ventricular strain for prediction of survival in pulmonary arterial hypertension. . Chest . 2011; ;139: : 1299– 1309 .
    [Google Scholar]
http://instance.metastore.ingenta.com/content/journals/10.5339/gcsp.2015.48
Loading
/content/journals/10.5339/gcsp.2015.48
Loading

Data & Media loading...

  • Article Type: Research Article
This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error